Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy

Author： Modi Marlene   Martin Nancy   Heathcote Jenny E   Nieforth Keith   Zeuzem Stefan  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.10, Iss.12, 2001-12, pp. : 2201-2213

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Peginterferon-α2a (40 kDa) for chronic hepatitis C

By Hadziyannis Stephanos J   Papatheodoridis George V  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 4, 2003-04 ,pp. : 541-551

Informa Healthcare

Access to resources Recommend Favorite

Peginterferon alfa-2b and ribavirin combination therapy for chronic hepatitis C

By Yeh Frank   Gordon Fredric D  

Future Virology, Vol. 2, Iss. 6, 2007-11 ,pp. : 553-563

Future Medicine

Access to resources Recommend Favorite

Peginterferon- -2a (40kD) Plus Ribavirin: A Review of its Use in the Management of Chronic Hepatitis C

By Keating G.M.   Curran M.P.  

Drugs, Vol. 63, Iss. 7, 2003-01 ,pp. : 701-730

Adis International

Access to resources Recommend Favorite

Peginterferon- -2a (40kD): A Review of its Use in the Management of Chronic Hepatitis C

By Perry C.M.   Jarvis B.  

Drugs, Vol. 61, Iss. 15, 2001-01 ,pp. : 2263-2288

Adis International

Access to resources Recommend Favorite

Peginterferon -2a (40kD) [Pegasys ® ] Improves HR-QOL Outcomes Compared with Unmodified Interferon -2a [Roferon ® -A]: In Patients with Chronic Hepatitis C

By Rasenack J.  

PharmacoEconomics, Vol. 21, Iss. 5, 2003-01 ,pp. : 341-349

Adis International

Access to resources Recommend Favorite